Mammoth Biosciences

Mammoth Biosciences is a biotechnology company focused on harnessing CRISPR technology for novel diagnostic and therapeutic applications. Founded in 2017 by a team including Nobel laureate Jennifer Doudna, the company aims to translate CRISPR discoveries into tools that democratize detection of diseases and genetic conditions. Its core platform leverages novel, compact Cas proteins discovered through bioinformatics to enable rapid, accurate, and portable testing. Mammoth has secured significant venture capital funding and established partnerships with major entities like Bayer and the United States Department of Defense.

History and founding

Mammoth Biosciences was established in 2017 by Trevor Martin, Janice Chen, Lucas Harrington, and Jennifer Doudna, a pioneer in CRISPR research from the University of California, Berkeley. The founding team sought to commercialize Doudna's groundbreaking work on the CRISPR-Cas9 system, for which she later shared the Nobel Prize in Chemistry. Initial operations were based in the San Francisco Bay Area, leveraging the region's dense network of venture capital firms and biotech expertise. The company's early research was supported by grants from institutions like the National Institutes of Health and seed funding from investors such as Mayfield Fund and NFX. Its name reflects the ambition to tackle large, "mammoth" challenges in human health through genetic engineering.

Technology and CRISPR platform

The company's technology is built around the discovery and engineering of novel, ultra-small Cas proteins, including Cas14 and CasΦ, which are significantly smaller than the commonly used Cas9. These compact enzymes, identified through computational analysis of microbial genomes, are central to Mammoth's DETECTR platform for diagnostics. The platform utilizes the collateral cleavage activity of certain Cas proteins to produce a fluorescent signal upon target recognition, enabling sensitive detection of specific DNA or RNA sequences. This approach allows for the development of rapid, paper-strip-based tests similar to a pregnancy test, facilitating point-of-care diagnosis without complex laboratory equipment. The company continues to expand its toolbox through partnerships with academic labs and its own internal protein engineering efforts.

Products and applications

Mammoth's primary product focus is on CRISPR-based diagnostic tests for infectious diseases, genetic mutations, and other health indicators. Its SARS-CoV-2 test was one of the first CRISPR-based diagnostics to receive an Emergency Use Authorization from the U.S. Food and Drug Administration. The company is developing assays for a range of pathogens, including human papillomavirus and influenza, as well as for oncology applications like detecting KRAS mutations. Beyond human health, its technology has potential applications in agriculture for pathogen detection in crops, veterinary medicine, and environmental monitoring. The long-term therapeutic vision includes using its compact Cas proteins for gene editing in vivo, potentially overcoming delivery challenges associated with larger systems like SpCas9.

Partnerships and collaborations

Mammoth has pursued an active partnership strategy to advance and deploy its technology. A major multi-year collaboration with the pharmaceutical giant Bayer aims to develop in vivo gene-editing therapies for serious diseases. The company has also worked with the United States Department of Defense and the Defense Advanced Research Projects Agency on biosecurity and rapid pathogen detection projects. In the consumer diagnostics space, it entered a partnership with GSK Consumer Healthcare to explore at-home testing platforms. Additional research collaborations with institutions like Stanford University and the University of California, San Francisco help fuel its discovery pipeline. These alliances provide non-dilutive funding, research expertise, and pathways to commercialization in diverse markets.

Company leadership and funding

The company is led by co-founder and CEO Trevor Martin, who holds a doctorate in biology from Stanford University. Its scientific co-founders, including Janice Chen and Lucas Harrington, maintain active roles in research and development. The board includes representatives from major investment firms and seasoned executives from the biopharmaceutical industry. Mammoth has raised substantial venture capital, with a significant Series D round in 2021 led by Redmile Group and including Fidelity Management and Research Company and Senator Investment Group. Earlier investors include Decheng Capital, Mayfield Fund, and NFX. The company's headquarters are in Brisbane, California, within the burgeoning Mission Bay biotech cluster. Category:Biotechnology companies of the United States Category:Companies based in San Mateo County, California Category:CRISPR companies Category:2017 establishments in California